Asthma, a chronic respiratory disorder, has emerged as a significant global health concern, affecting millions of individuals worldwide. The prevalence of asthma has been steadily rising, causing a substantial economic and mental burden among those affected. As one of the most common respiratory diseases, asthma has become a major cause of mortality across the globe. In recent years, the number of asthma cases has seen a significant surge, and according to the World Health Organization (WHO), the proliferation of asthma has been relentless. In 2019 alone, approximately 262 million individuals were affected by asthma, leading to around 455,000 recorded deaths. Furthermore, WHO estimates suggest that about 339 million individuals develop asthma annually, with older adults being more susceptible to fatal outcomes.
For more information, please refer to the full report: https://www.fairfieldmarketresearch.com/report/asthma-treatment-market The Global Initiative for Asthma 2020 report highlights the increasing prevalence of asthma in various countries, affecting anywhere from 1% to 18% of the population. This alarming trend has necessitated the development of advanced therapeutics to effectively treat the disease, leading to an expansion of the asthma treatment market. The rising burden of asthma has become a driving force behind the growth of this market, prompting the need for long-term control medications and quick relief asthma medications. The Impact of COVID-19 on Asthma Treatment Market